| Literature DB >> 29099785 |
Yuhao Sun1,2,3, Xiaolin Chen4,5, Ziqiang Cheng6, Song Liu7,8, Huahua Yu9,10, Xueqin Wang11,12, Pengcheng Li13,14.
Abstract
In this study, polysaccharides from Grateloupia filicinia (GFP) were extracted and several low molecular weight (Mw) G. filicina polysaccharides (LGFPs) were prepared by the hydrogen peroxide (H₂O₂) oxidation method. Additionally, the effect of different experimental conditions on the degradation of GFP was determined. Results showed that the GFP degradation rate was positively related to H₂O₂ concentration and temperature, and negatively related to pH. Chemical analysis and Fourier transform infrared spectra (FT-IR) of GFP and LGFPs showed that the degradation caused a slight decrease of total sugar and sulfate content. However, there was no obvious change for monosaccharide contents. Then, the anti-ALV-J activity of GFP and LGFPs were determined in vitro. Results revealed that all of the samples could significantly inhibit ALV-J and lower Mw LGFPs exhibited a stronger suppression, and that the fraction LGFP-3 with Mw 8.7 kDa had the best effect. In addition, the reaction phase assays showed that the inhibition effect was mainly because of the blocking virus adsorption to host cells. Moreover, real-time PCR, western-blot, and IFA were further applied to evaluate the blocking effects of LGFP-3. Results showed that the gene relative expression and gp85 protein for LGFPS-3 groups were all reduced. Data from IFA showed that there was less virus infected cells for 1000 and 200 μg/mL LGFPS-3 groups when compared to virus control. Therefore, lower Mw polysaccharides from G. filicina might supply a good choice for ALV-J prevention and treatment.Entities:
Keywords: ALV-J; Grateloupia filicina; antiviral activity; degradation; low molecular weight polysaccharides
Mesh:
Substances:
Year: 2017 PMID: 29099785 PMCID: PMC5706035 DOI: 10.3390/md15110345
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Effects of temperature on the molecular weight (Mw) of Grateloupia filicinia polysaccharide (GFP). The reaction was carried out in pH 1 and 0.15% H2O2 under different temperature conditions.
Figure 2Effect of H2O2 concentration on the Mw of GFP. GFP was degraded at pH 1 and 90 °C under different H2O2 concentration conditions.
Figure 3Effects of pH on the Mw of GFP. GFP was degraded in 0.3% H2O2 at 90 °C under different pH conditions.
Preparation conditions and yield of LGFPs.
| Sample | Temperature (°C) | pH | H2O2 (%) | Time (min) | Yield (%) |
|---|---|---|---|---|---|
| LGFP-1 | 90 | 4 | 0.3 | 75 | 73.4 |
| LGFP-2 | 90 | 4 | 0.3 | 135 | 46.28 |
| LGFP-3 | 90 | 4 | 0.3 | 210 | 42.99 |
| LGFP-4 | 90 | 4 | 0.3 | 240 | 40.38 |
Figure 4HPLC profiles of the GFP and LGFPs.
Chemical composition of polysaccharides (%w/w of dry weight).
| Sample | Total Sugar (%) | Sulfate (%) | Protein (%) | Mw (kDa) | Monosaccharides Composition (Molar Ratio) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Man | Rha | Glc A | Glc | Gal | Xyl | Fuc | |||||
| GFP | 55.22 ± 0.96 | 21.52 ± 0.04 | 1.45 ± 0.08 | 216.7 ± 1.2 | 0.00 | 0.01 | 0.03 | 0.01 | 1 | 0.03 | 0.03 |
| LGFP-1 | 49.74 ± 1.22 | 20.99 ± 0.28 | 0.96 ± 0.01 | 40.2 ± 0.3 | 0.01 | 0.01 | 0.03 | 0.01 | 1 | 0.03 | 0.02 |
| LGFP-2 | 47.21 ± 1.32 | 16.86 ± 0.10 | 0.45 ± 0.02 | 14.0 ± 0.3 | 0.01 | 0.01 | 0.05 | 0.01 | 1 | 0.03 | 0.02 |
| LGFP-3 | 44.73 ± 2.43 | 18.33 ± 0.43 | 0.18 ± 0.01 | 8.7 ± 0.2 | 0.01 | 0.01 | 0.05 | 0.01 | 1 | 0.03 | 0.01 |
| LGFP-4 | 41.00 ± 0.25 | 17.01 ± 0.44 | 0.29 ± 0.00 | 2.7 ± 0.1 | 0.01 | 0.02 | 0.04 | 0.01 | 1 | 0.02 | 0.02 |
Man: mannose; Rha: rhamnose; Glc A: glucuronic acid; Glc: glucose; Gal: galactose; Xyl: xylose; Fuc: fucose.
Figure 5Fourier transform infrared (FT-IR) spectra of GFP and LGFPs in regions from 4000 to 500 cm−1.
Relative Survival Rate of DF-1 cells.
| Concentration (mg/mL) | 2 | 1 | 0.5 | 0.25 | 0.125 | 0.0625 | 0.03125 |
|---|---|---|---|---|---|---|---|
| GFP | 0.95 ± 0.02 | 1.00 ± 0.06 | 1.03 ± 0.07 | 1.08 ± 0.01 | 1.07 ± 0.04 | 1.05 ± 0.09 | 1.02 ± 0.06 |
| LGFP-1 | 0.96 ± 0.02 | 1.00 ± 0.05 | 1.05 ± 0.04 | 1.05 ± 0.08 | 1.01 ± 0.04 | 0.99 ± 0.04 | 1.00 ± 0.04 |
| LGFP-2 | 0.9 4± 0.05 | 1.06 ± 0.04 | 1.01 ± 0.02 | 1.05 ± 0.04 | 1.05 ± 0.05 | 1.01 ± 0.04 | 1.03 ± 0.07 |
| LGFP-3 | 0.9 5± 0.02 | 1.02 ± 0.05 | 1.04 ± 0.10 | 0.99 ± 0.03 | 1.03 ± 0.03 | 0.99 ± 0.05 | 1.03 ± 0.04 |
| LGFP-4 | 0.96 ± 0.10 | 0.98 ± 0.03 | 1.03 ± 0.06 | 1.01 ± 0.05 | 1.01 ± 0.03 | 1.04 ± 0.07 | 1.09 ± 0.03 |
The safe concentration of GFP and LGFPs was tested using MTT assay. All treatments were performed in triplicate. The relative survival rate reflected the cytotoxity of GFP and LGFPs.
Figure 6Expression of ALV-J p27 antigen. Antiviral activity of GFP and LGFPs were determined by ALV p27 antigen test kit. Results are recognized as positive when S/P value is greater than 0.2. Data are shown as the Mean + SD. Values with different letters in the same column (a–f) are significantly different (p < 0.05) from each other.
Figure 7Expression of p27 after different modes of administration: LGFP-3 treated DF-1 cells before adsorption (BA); LGFP-3 treated virus at the adsorption phase (Ad); and, LGFP-3 treated DF-1 cells after adsorption (AA). The final concentrations of LGFP-3 were all 1 mg/mL in these three administration. DF-1 cells with and without inoculation were used as the virus and cell control, respectively. Data are shown as the Mean + SD. Values with different letters in the same column (a–c) are significantly different (p < 0.05) from each other.
Figure 8Gene relative expression of ALV-J measured with real-time PCR. DF-1 cells with or without inoculation were used as the virus and cell control, respectively. Data are shown as the Mean + SD. Values with different letters in the same column (a–d) are significantly different (p < 0.05) from each other.
Figure 9Expression of ALV-J gp85 protein evaluated by western-blot. DF-1 cells with or without inoculation were used as the virus and cell control, respectively.
Figure 10Expression of ALV-J gp85 protein evaluated by IFA. (a): virus control; (b): cell control; (c): ALV-J treated with 40 μg/mL LGFP-3; (d): ALV-J treated with 200 μg/mL LGFP-3; and, (e): ALV-J treated with 1000 μg/mL LGFP-3.